Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin on Vascular Health in T2DM
NCT05139914Phase 4Terminated
- Sponsor
- Boston University
- Start
- May 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and endothelial dysfunction (2 arms), sponsored by Boston University. Primary endpoints: Mean Systolic Blood Pressure at 14 weeks and Mean Diastolic Blood Pressure at 14 weeks. Started May 2022; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)endothelial dysfunction
Beyond the preview
Go deeper on NCT05139914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05139914.